Archives of General Internal Medicine

Reach Us +1 (202) 780-3397

Editorial - Archives of General Internal Medicine (2024) Volume 8, Issue 4

Common Disorders of the Parathyroid Glands: Diagnosis and Treatment

David Cam *

Department of General Surgery, Zhejiang University, USA

*Corresponding Author:
David Cam
Department of General Surgery, Zhejiang University, USA
E-mail: dacam5678@zu.us

Received: 29-Jul-2024, Manuscript No. AAAGIM-24-145858; Editor assigned: 01-Aug-2024, PreQC No. AAAGIM-24-145858 (PQ); Reviewed:14-Aug-2024, QC No. AAAGIM-24-145858; Revised:19-Aug-2024, Manuscript No. AAAGIM-24-145858(R); Published:26-Aug-2024, DOI:10.35841/aara-8.4.242

Citation: Cam D. Common disorders of the parathyroid glands: Diagnosis and treatment. Arch Gen Intern Med. 2024;8(4):242.

Visit for more related articles at Archives of General Internal Medicine

Abstract

  

Introduction

The parathyroid glands, small endocrine organs located behind the thyroid gland in the neck, play a crucial role in regulating calcium levels in the bloodstream and bone metabolism. Disorders of these glands can lead to significant health issues, as they impact calcium homeostasis and overall metabolic function. Understanding the common disorders of the parathyroid glands, along with their diagnosis and treatment, is essential for maintaining a healthy balance in the body. One of the most common parathyroid disorders is primary hyperparathyroidism. This condition occurs when one or more of the parathyroid glands become overactive and produce excessive amounts of Parathyroid Hormone (PTH). Elevated PTH levels lead to increased calcium release from the bones into the bloodstream, which can result in high blood calcium levels [1, 2].

Symptoms of primary hyperparathyroidism can vary widely but often include fatigue, muscle weakness, depression, kidney stones, and bone pain. In some cases, the condition may be asymptomatic and discovered incidentally during routine blood tests. Primary hyperparathyroidism is frequently caused by benign tumors known as parathyroid adenomas, which are responsible for the overproduction of PTH. However, other potential causes include parathyroid hyperplasia, where multiple glands are enlarged and overactive, or, more rarely, parathyroid carcinoma, a malignant tumor of the parathyroid glands. Diagnosis typically involves measuring serum calcium and PTH levels. An elevated serum calcium level alongside an elevated or normal PTH level is indicative of primary hyperparathyroidism. Further imaging studies, such as a sestamibi scan or ultrasound, may be performed to localize the affected gland or glands [3, 4].

Treatment for primary hyperparathyroidism generally involves surgical intervention, particularly if the condition is symptomatic or if there is evidence of complications such as significant bone loss or kidney stones. The goal of surgery is to remove the hyperfunctioning parathyroid tissue while preserving normal parathyroid function. For cases where surgery is not feasible or if the patient is asymptomatic, management may include monitoring and addressing symptoms. In some instances, medication such as bisphosphonates or calcimimetics may be used to help manage the condition. Secondary hyperparathyroidism is another disorder that arises when the parathyroid glands become overactive due to another underlying condition. Unlike primary hyperparathyroidism, secondary hyperparathyroidism is not caused by an intrinsic problem with the parathyroid glands themselves but rather a response to low blood calcium levels [5, 6].

This condition is often seen in chronic kidney disease, where the kidneys are unable to adequately excrete phosphate, leading to a drop in serum calcium levels. In response, the parathyroid glands increase PTH production to compensate for the low calcium levels. Diagnosis of secondary hyperparathyroidism involves measuring serum calcium, phosphate, and PTH levels. Typically, serum calcium levels are low or normal, while serum phosphate levels may be elevated. Treatment of secondary hyperparathyroidism focuses on addressing the underlying cause. For patients with chronic kidney disease, managing phosphate levels through dietary restrictions and phosphate binders is essential. In some cases, active vitamin D analogs may be prescribed to help improve calcium absorption and manage PTH levels. In advanced cases, surgical intervention may be considered to remove some of the parathyroid glands if medical management is insufficient [7, 8].

Tertiary hyperparathyroidism is a more complex condition that can occur as a progression of secondary hyperparathyroidism. It is characterized by the development of autonomous parathyroid hyperfunction, even after the underlying cause has been treated or resolved. This often occurs in patients with long-standing secondary hyperparathyroidism, such as those with end-stage renal disease who have undergone kidney transplantation. Despite improvements in calcium and phosphate levels after transplantation, the parathyroid glands may continue to produce excess PTH [9, 10].

Conclusion

Overall, disorders of the parathyroid glands encompass a range of conditions, each with its own diagnostic and treatment considerations. Primary hyperparathyroidism, secondary hyperparathyroidism, tertiary hyperparathyroidism, and hypoparathyroidism each present unique challenges in terms of diagnosis and management. A thorough understanding of these conditions is essential for healthcare providers to offer appropriate treatment and improve patient outcomes. Advances in diagnostic techniques and treatment options continue to enhance the ability to effectively manage parathyroid gland disorders and maintain overall health.

References

  1. Jamshidi R, Egan JC. Pediatric parathyroid disease. Semin Pediatr Surg. 2020;29(3): 150923.
  2.  Indexed atGoogle ScholarCross Ref

  3. Kose E, Rudin AV, Kahramangil B, et al. Autofluorescence imaging of parathyroid glands: An assessment of potential indications. Surgery. 2020;167(1):173-9.
  4. Indexed atGoogle ScholarCross Ref

  5. Marsden M, Weaver SS, Marcu L, et al. Intraoperative mapping of parathyroid glands using fluorescence lifetime imaging. J Surg Res. 2021;265:42-8.
  6. Indexed atGoogle ScholarCross Ref

  7. Cottrill EE. Avoiding Complications of Thyroidectomy: Preservation of Parathyroid Glands. Otolaryngol Clin North Am. 2023.
  8. Indexed atGoogle ScholarCross Ref

  9. Itani M, Middleton WD. Parathyroid imaging. Radiol Clin North Am. 2020;58(6):1071-83.
  10. Indexed atGoogle ScholarCross Ref

  11. Botushanova AD, Botushanov NP, Yaneva MP. Nuclear medicine methods for evaluation of abnormal parathyroid glands in patients with primary and secondary hyperparathyroidism. Folia Med. 2017;59(4):396-404.
  12. Indexed atGoogle ScholarCross Ref

  13. Graves CE, Duh QY, Suh I. Innovations in Parathyroid Localization Imaging. Surg Oncol Clin N Am. 2022;31(4):631-47.
  14. Indexed atGoogle ScholarCross Ref

  15. Pasternak JD. Finding Parathyroid Glands. Festchrift: Dr. Janice L Pasieka Oct 14, 2023. Am J Surg. 2024;232:152-3.
  16. Indexed atGoogle ScholarCross Ref

  17. Saljo K, Thornell A, Jin C, et al. Characterization of glycosphingolipids in the human parathyroid and thyroid glands. Int J Mol Sc. 2021;22(13):7044.
  18. Indexed atGoogle ScholarCross Ref

  19. Karcioglu AS, Hartl D, Shonka DC, et al. Autofluorescence of parathyroid glands: a review of methods of parathyroid gland identification and parathyroid vascular assessment. Otolaryngol Clin North Am. 2023.
  20. Indexed atGoogle ScholarCross Ref

     

Get the App